Funding Source
NIDA, UG1DA040309
Project Period
9/01/2015 – 2/29/2032
Principal Investigator
Lisa A. Marsch, PhD (Dartmouth College)
Other Project Staff
Co-Is: Luke Archibald, Kelly Aschbrenner, Jonathan Ballard, Steven, Bernstein, Jacob Borodovsky, Charlie Brackett, Mary Brunette, MD, Alan Budney, Steve Chapman, Lynn Fiellin, Daisy Goodman, Felicity Homsted, Nick Jacobson, Tricia Lanter, Sarah Lord, Varun Mishra, Sarah Moore, Milan Satcher, Elizabeth Saunders.
Research Project Director: Bethany McLeman
Regulatory Director; PAB Admin: Chantal Lambert-Harris
Training Director: Owen Murray
Data Manager: Scott Gerlach
Research Coordinator: Eilis Murphy
Project Director/QA Reg Lead: Kathleen Bell
Project Summary
The Northeast Node of the National Drug Abuse Treatment Clinical Trials Network (CTN) has been part of the national CTN since 2015. The Northeast Node has engaged a network of hundreds of community, healthcare, researcher, policy, and payor partners across the states of New Hampshire, Vermont, and Maine. These states have among the very highest rates of substance use and overdose mortality in the U.S. and include some of the most rural communities in the U.S. The Node has brought significant expertise to the CTN in successfully leading multi-site clinical trials as well as feasibility, efficacy, effectiveness, implementation, and hybrid implementation/effectiveness research studies focused on improving the prevention and treatment of substance use disorders (SUDs) and reducing harms of SUDs; community- and culturally-informed research; digital health, Artificial Intelligence, data science, data analytics, machine/deep learning, digital phenotyping and digital therapeutics for SUDs and related issues; and collaborating with health systems, research networks, community organizations and our SUD policymakers, state authorities and congressional delegates. The Node has also been a leader in many national CTN-wide initiatives, including launching and leading the first-of-its kind national Community Representative Council (CIRCL) to inform the work of the CTN across the nation and leading the strategic planning of the CTN, with PI Marsch serving as Chair of the national CTN Steering Committee. The Northeast Node’s research contributions to the CTN promote advances in scientific discovery that offer great promise for increasing the reach and effectiveness of treatments for SUDs that address both key and emerging substance use needs with a key focus on engaging and impacting underserved populations, including rural and socioeconomically disadvantaged communities and other health disparity populations. We seek to generate evidence to inform healthcare policy and payor decisions and scale-up and sustain best practices.
The Northeast Node’s supplemental research studies include:
CTN-0044: Web-delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders
CTN-0044-A2: Web-based Addiction Treatment: Cultural Adaptation with American Indians
CTN-0073: Towards Detecting Cocaine Use Using Smartwatches (NIDA Clinical Trials Network)
CTN-0079: Emergency Department Connection to Care with Buprenorphine for Opioid Use Disorder
CTN-0079-A1: Emergency Department Outcomes for Patients with Opioid Use Disorder
CTN-0083: Using Social Media to Deliver HIV Self-Testing Kits and Link to Online PrEP Services
CTN-0099: Emergency Department-INitiated bupreNOrphine and VAlidaTIOn Network Trial (ED-INNOVATION)
CTN-0101: Subthreshold Opioid Use Disorder Prevention (STOP) Trial
CTN-0102: Rural Expansion of Medication Treatment for Opioid Use Disorder
CTN-0102-XR: Rural Expansion of Medication Treatment for Opioid Use Disorder: Randomized Controlled Pilot Trial of Extended-release Buprenorphine vs. Sublingual Buprenorphine-naloxone in Rural Settings
CTN-0116: Pharmacist-Integrated Model of Medication Assisted Treatment for Opioid Use Disorder
CTN-0138: Adaptation and Implementation of a Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool
Public Health Relevance
The Northeast Node focuses on identifying the most significant and timely substance use needs in our communities, leading and partnering on rigorous and innovative research projects to tackle these challenges, and scaling-up and sustaining best practices in our nation.